Warning of a pullback in the innovative drug sector: Early signs of a retreat? Reduce positions for safety or buy the dip?

This morning, I took a look at the innovative drug sector, which has generally seen some pullbacks and adjustments. Big players like Hengrui Medicine and WuXi AppTec are no exception. Here's the conclusion: I still believe the sector hasn't peaked yet. However, signs of a short-term high are emerging, and a period of adjustment and pullback is expected in the future.

While we should remain firmly optimistic, our strategy shouldn't be rigid. We should avoid pullbacks as much as possible—or at least minimize them. After all, the market is still a game of sentiment. For those holding innovative drug ETFs, it's advisable to at least reduce half of the position. There's no rush to re-enter until the adjustment is over. This isn't just about this sector; the broader trend suggests reducing positions across the board.
Being conservative with an empty position is a strategy, and so is being fully invested. Friends trading individual stocks can also take this as a reference.
Follow Old E to uncover the deeper logic behind the trends in Hong Kong and U.S. stocks~

$HENGRUI PHARMA(01276.HK) $WUXI APPTEC(02359.HK) $Yinhua CNI HK Connect Innovative Drugs ETF(159567.SZ)